An intense and high-touch study, the patients are followed monthly for six months (CPET, cognitive testing) and have a 12-month follow-up
By 48 weeks, significant average weight loss was seen at all maintenance doses: With longer treatment lasting up to 68 weeks, weight loss continued, particularly at higher doses: 12mg: average weight loss of up to 28.7% of body weight This longer-term data shows that weight loss with retatrutide can continue beyond one year, rather than plateauing early, especially at higher maintenance doses
One of the advanced tools we offer is tirzepatide , a medication originally developed for type 2 diabetes that has shown significant benefits in supporting weight loss for individuals with obesity or overweight conditions
FDA approval may happen in late 2026 or early 2027
Quick Answer: Tirzepatide does not require lifelong use for all patients, but most individuals need ongoing therapy to maintain blood sugar control and weight loss benefits since type 2 diabetes and obesity are chronic conditions
